排版丨水成文 胶质母细胞瘤 （GBM） 是成年人中最常见、最具侵袭性的恶性脑肿瘤。胶质母细胞瘤 表现出显著的异质 性， 患者在确诊后通常只能存活 12-18 个月。 尽管经过了几十年的研究，但该疾病尚无治愈方法，而且 已批准的治疗方法 （例如手术、放疗和化疗） 在延长患者预期寿命方面效果有限。 胶质母细胞瘤干细胞 （GSC） 对多种疗法具有耐药性，是术后胶质母细胞瘤 （GBM） 复发的重要驱动因 素。减少 GSC 数量在胶质母细胞瘤的治疗中极具前景，但由于难以协调诱导 GSC 扩增的复杂细胞因子信 号程序和细胞外基质特性，这一治疗策略仍然具有挑战性。 2025 年 12 月 26 日，福州大学林立森教授团队联合新加坡国立大学陈小元教授团队，在 Nature 子刊 Nature Nanotechnology 上发表了题为： A biohybrid chiral hydrogel enhances preclinical postoperative glioblastoma therapy by multi-pronged inhibition of tumour stemness 的研究论文。 撰文丨王聪 编辑 ...

Core Viewpoint - The study identifies BRD9 as a key regulator of glioblastoma's resistance to oncolytic virus therapy, suggesting that inhibiting BRD9 can enhance the efficacy of such treatments [4][10]. Group 1: Research Findings - The research utilized a genome-wide CRISPR screening approach to discover that BRD9 is a critical factor in tumor resistance to oncolytic virus therapy [4][8]. - Inhibition of BRD9 significantly enhances the replication and anti-tumor effects of oncolytic herpes simplex virus type 1 (oHSV1), indicating a potential therapeutic value when combined with BRD9 inhibitors [6][10]. - BRD9 interacts with RELA to regulate the expression of antiviral genes, which is crucial for the effectiveness of oHSV1 therapy [7][8]. Group 2: Clinical Implications - The study suggests that BRD9 levels could serve as a potential biomarker for predicting clinical outcomes in oHSV1 therapy for glioblastoma patients [8][10]. - The findings highlight the importance of developing strategies to target BRD9 in order to overcome the resistance seen in glioblastoma treatments [10].